• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS One The Influenza Replication Blocking Inhibitor LASAG Does Not Sensitize Human Epithelial Cells for Bacterial Infections

tetano

Editor, Senior Moderator
PLoS One


. 2020 May 15;15(5):e0233052.
doi: 10.1371/journal.pone.0233052. eCollection 2020.
The Influenza Replication Blocking Inhibitor LASAG Does Not Sensitize Human Epithelial Cells for Bacterial Infections


Janine J Wilden[SUP] 1 [/SUP], Andre van Kr?chten[SUP] 1 [/SUP], Lutz Gieselmann[SUP] 1 [/SUP], Eike R Hrincius[SUP] 1 [/SUP], Stefanie Deinhardt-Emmer[SUP] 2 [/SUP], Karoline F Haupt[SUP] 2 [/SUP], Hannah F Preugschas[SUP] 1 [/SUP], Silke Niemann[SUP] 3 [/SUP], Stephan Ludwig[SUP] 1 4 [/SUP], Christina Ehrhardt[SUP] 1 2 [/SUP]



Affiliations
Free article

Abstract

Severe influenza virus (IV) infections still represent a major challenge to public health. To combat IV infections, vaccines and antiviral compounds are available. However, vaccine efficacies vary with very limited to no protection against newly emerging zoonotic IV introductions. In addition, the development of resistant virus variants against currently available antivirals can be rapidly detected, in consequence demanding the design of novel antiviral strategies. Virus supportive cellular signaling cascades, such as the NF-κB pathway, have been identified to be promising antiviral targets against IV in in vitro and in vivo studies and clinical trials. While administration of NF-κB pathway inhibiting agents, such as LASAG results in decreased IV replication, it remained unclear whether blocking of NF-κB might sensitize cells to secondary bacterial infections, which often come along with viral infections. Thus, we examined IV and Staphylococcus aureus growth during LASAG treatment. Interestingly, our data reveal that the presence of LASAG during superinfection still leads to reduced IV titers. Furthermore, the inhibition of the NF-κB pathway resulted in decreased intracellular Staphylococcus aureus loads within epithelial cells, indicating a dependency on the pathway for bacterial uptake. Unfortunately, so far it is not entirely clear if this phenomenon might be a drawback in bacterial clearance during infection.
 
Back
Top Bottom